| Wissenschaftl. Titel | A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy |
| Erkrankung |
Geschlechtsorgane:
Brustkrebs:
adjuvant
|
| Molekularer Marker |
BRCA Triple neg (HER2/ER/PR neg) HER2/neu neg./ER pos. HER2/neu neg./PR pos. |
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 13.11.2015 Alexandra Lucaciu
geändert 20.04.2020 Student Studienregister